SAN FRANCISCO, Aug. 14, 2026 /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.Â
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
LOS ANGELES, Aug. 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding Embecta Corp. Shares: $5.35 Per-Share Loss Raises Lead Plaintiff Considerations for Institutional Holders
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category.
LOS ANGELES, July 28, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.
